開能健康(300272.SZ):高森投資已減持524.5118萬股 其持股降至4.99998%
格隆匯10月13日丨開能健康(300272.SZ)公佈,2021年10月13日,公司收到持股5%以上股東上海高森投資有限公司(“高森投資” )發來的《關於股份減持的吿知函》及《簡式權益變動報吿書》,高森投資於2021年8月16日至2021年10月12日通過集中競價交易方式減持公司股份524.5118萬股,佔公司總股本(指剔除回購專用賬户中股份數量後的公司股本566,871,449股,下同)的0.9253%。
截至2021年10月12日,高森投資持有公司股份2834.3455萬股,佔公司總股本的4.99998%,不再是持有公司5%以上股份的股東。此次減持計劃尚未實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.